B3GAT1 and Miyoshi myopathy: Importantly, at +30 and +100 days after auto-HSCT, MM patients with a lower frequency of mature, well-differentiated NKG2A-CD57+ NK cell subsets had a better PFS to the next treatment than those with a higher frequency (98).